PapersFlow Research Brief

Migraine and Headache Studies
Research Guide

What is Migraine and Headache Studies?

Migraine and Headache Studies is the interdisciplinary research field that defines, classifies, measures, and treats migraine and other headache disorders using standardized diagnostic criteria, epidemiologic burden estimates, and clinical trials of acute and preventive interventions.

Migraine and Headache Studies is anchored by shared diagnostic standards, most prominently the International Classification of Headache Disorders, including "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition" (2018) and "The International Classification of Headache Disorders: 2nd edition" (2003). The provided topic corpus contains 96,907 works, while the 5-year growth rate is listed as N/A. High-citation subareas in the provided list include global burden measurement (e.g., "The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide" (2007)) and preventive therapy evidence (e.g., "Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study" (1988)).

96.9K
Papers
N/A
5yr Growth
1.4M
Total Citations

Research Sub-Topics

Why It Matters

Standardized classification enables consistent diagnosis, comparable clinical trials, and interoperable surveillance of headache disorders across clinics and countries. "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition" (2018) provides the shared diagnostic vocabulary that underpins inclusion/exclusion criteria in trials and case definitions in epidemiology, while "The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide" (2007) operationalizes how headache prevalence and disability are quantified in population-based studies applying International Headache Society criteria. Preventive treatment decisions also have immediate clinical and health-system consequences: Lipton et al. (2007) reported that “more than one in four migraineurs are candidates for preventive therapy,” yet “a substantial proportion of those who might benefit from prevention do not receive it,” framing a concrete care gap that motivates screening, guideline implementation, and pragmatic trials. In pediatrics, Sorge et al. (1988) evaluated a specific prophylactic regimen—flunarizine 5 mg/day—in an 8-month, double-blind, placebo-controlled, crossover trial in 70 children, illustrating how headache research directly informs dosing, trial design, and evidence-based preventive options for vulnerable populations.

Reading Guide

Where to Start

Start with "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition" (2018) because it provides the shared diagnostic definitions that determine who is counted as having migraine or other headache disorders in nearly all subsequent clinical and epidemiologic research.

Key Papers Explained

A practical reading sequence is to move from definitions to burden to treatment. "The International Classification of Headache Disorders: 2nd edition" (2003) establishes the historical framework for standardized criteria, while "The International Classification of Headache Disorders, 3rd edition (beta version)" (2013) and "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition" (2018) represent the modern standardization that enables consistent study inclusion criteria. Once definitions are clear, Stovner et al. (2007) in "The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide" illustrates how IHS criteria are used to synthesize population prevalence and disability evidence, and Lipton et al. (2007) in "Migraine prevalence, disease burden, and the need for preventive therapy" connects burden to clinical action by quantifying preventive-therapy candidacy and undersupply. For intervention evidence in a specific population, Sorge et al. (1988) in "Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study" provides a concrete example of trial design, dosing (5 mg/day), and pediatric prophylaxis evaluation.

Paper Timeline

100%
graph LR P0["Flunarizine in Prophylaxis of Ch...
1988 · 3.5K cites"] P1["The International Classification...
2003 · 5.1K cites"] P2["A Report on the Journal 2004
2004 · 2.4K cites"] P3["The Global Burden of Headache: A...
2007 · 2.4K cites"] P4["The International Classification...
2013 · 8.1K cites"] P5["Interplay between Cortical Sprea...
2017 · 3.7K cites"] P6["Headache Classification Committe...
2018 · 9.9K cites"] P0 --> P1 P1 --> P2 P2 --> P3 P3 --> P4 P4 --> P5 P5 --> P6 style P6 fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan

Most-cited paper highlighted in red. Papers ordered chronologically.

Advanced Directions

Within the boundaries of the provided list, an advanced direction is to align mechanistic hypotheses with standardized clinical phenotyping: Kramer et al. (2017) in "Interplay between Cortical Spreading Depolarization and Seizures" motivates designs that connect electrophysiologic phenomena to clinically classified headache presentations under ICHD-3. Another advanced direction is outcomes harmonization across studies by combining ICHD-based diagnosis with validated patient-reported measures, using the SF-36 foundation described by Aaronson et al. (1998) in "Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations".

Papers at a Glance

In the News

Code & Tools

Recent Preprints

Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 - PubMed

Dec 2025 pubmed.ncbi.nlm.nih.gov Preprint

**Background:**The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 estimates health loss from migraine, tension-type headache, and medication-overuse headache. This study pre...

Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Nov 2025 healthdata.org Preprint

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 estimates health loss from migraine, tension-type headache, and medication-overuse headache. This study presents updated r...

Global, regional, and national burden of headache disorders, 1990–2021, and projections to 2050: a comprehensive analysis of the global burden of disease study 2021

Oct 2025 frontiersin.org Preprint

**Introduction:**Headache disorders, including migraines and tension-type headaches, are prevalent and debilitating conditions that affect millions of people worldwide. And this analysis aims to in...

Global, regional, and national burden of headache disorders, 1990-2021, with forecasts to 2050: A Global Burden of Disease study 2021 - PubMed

Sep 2025 pubmed.ncbi.nlm.nih.gov Preprint

doi: 10.1016/j.xcrm.2025.102348.Epub 2025 Sep 18. # Global, regional, and national burden of headache disorders, 1990-2021, with forecasts to 2050: A Global Burden of Disease study 2021

The global and regional burden and trends of migraine from 1990 to 2021: Global Burden of Disease Study 2021

Nov 2025 frontiersin.org Preprint

**Background:**Migraine is a common disabling neurological disorder that affects the quality of human daily life and mental health, potentially leading to disability and imposing a substantial dise...

Latest Developments

Recent developments in migraine and headache research include promising results from a Phase 4 trial showing that fremanezumab injections can significantly reduce migraine days in children (scienceblog.cincinnatichildrens.org, published January 14, 2026), advancements in neuromodulation techniques (link.springer.com, published February 15, 2025), and ongoing studies on new medications such as elismetrep, a novel oral treatment targeting neural circuits (kallyope.com, published January 7, 2026). Additionally, recent research highlights the efficacy of CGRP monoclonal antibodies like Ajovy and other targeted therapies, as well as innovative approaches addressing early migraine symptoms (bmj.com, published September 12, 2025; nature.com, published May 12, 2025).

Frequently Asked Questions

What is the International Classification of Headache Disorders (ICHD) and why is it central to headache research?

The ICHD is the standard diagnostic and classification system for headache disorders used to define research case definitions and clinical diagnoses. "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition" (2018) and "The International Classification of Headache Disorders: 2nd edition" (2003) are widely used reference points that allow studies to apply consistent criteria across sites and time.

How do researchers measure the population burden of headache disorders in a comparable way across countries?

Burden studies typically rely on population-based designs that apply International Headache Society diagnostic criteria and then quantify prevalence and disability. Stovner et al. (2007) in "The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide" described compiling worldwide evidence on prevalence and burden from studies using these criteria.

Which evidence in the provided list supports preventive therapy for migraine, and what trial design features matter?

Sorge et al. (1988) in "Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study" tested flunarizine 5 mg/day in an 8-month double-blind, placebo-controlled crossover trial involving 70 children. The crossover and placebo control are key design features for separating medication effects from natural fluctuation and expectancy effects in migraine outcomes.

Why do many migraine patients remain untreated with preventive therapy despite being eligible?

Lipton et al. (2007) in "Migraine prevalence, disease burden, and the need for preventive therapy" stated that “more than one in four migraineurs are candidates for preventive therapy,” while “a substantial proportion of those who might benefit from prevention do not receive it.” This implies that identifying candidates and implementing prevention in routine care are persistent translational challenges even when epidemiology indicates need.

Which papers in the provided list are most useful for understanding diagnostic standards versus mechanisms?

For diagnostic standards, the core references are "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition" (2018), "The International Classification of Headache Disorders, 3rd edition (beta version)" (2013), and "The International Classification of Headache Disorders: 2nd edition" (2003). For a mechanistic lens related to migraine-relevant neurophysiology, Kramer et al. (2017) in "Interplay between Cortical Spreading Depolarization and Seizures" discusses cortical spreading depolarization and its relationship to seizure phenomena.

Which general-purpose health status instrument appears in the provided list and how might it be used in headache studies?

Aaronson et al. (1998) in "Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations" provides evidence for a standardized health-related quality-of-life measure. In headache studies, such instruments can be used to quantify broader functional impact beyond headache frequency or intensity, enabling comparisons across conditions and populations.

Open Research Questions

  • ? Which ICHD-3 diagnostic boundaries most strongly influence estimates of headache prevalence and disability when applied in population-based studies, as exemplified by the approach summarized in "The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide" (2007)?
  • ? How can preventive-therapy eligibility criteria be operationalized in routine care to reduce the treatment gap described in "Migraine prevalence, disease burden, and the need for preventive therapy" (2007)?
  • ? Which patient subgroups (e.g., pediatric phenotypes) benefit most from flunarizine prophylaxis, and what outcome measures best capture benefit in designs like "Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study" (1988)?
  • ? How should headache studies integrate mechanistic constructs such as cortical spreading depolarization in human research designs while maintaining clinically meaningful endpoints, in light of the framing in "Interplay between Cortical Spreading Depolarization and Seizures" (2017)?
  • ? Which minimum dataset (diagnostic criteria, disability, and quality-of-life metrics) best supports comparability across trials and population studies when combining ICHD-based diagnosis with generic health status tools like the SF-36 as presented in "Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations" (1998)?

Research Migraine and Headache Studies with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching Migraine and Headache Studies with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.